tiprankstipranks
Advertisement
Advertisement

DE:22UA Stock Latest News

BioNTech price target raised to $126 from $125 at Morgan Stanley
The FlyBioNTech price target raised to $126 from $125 at Morgan Stanley
11h ago
BNTX
BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID
PremiumCompany Announcements
BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID
6d ago
BNTX
BioNTech Calls Virtual 2026 AGM, Seeks Larger Supervisory Board to Back Oncology Push
PremiumCompany Announcements
BioNTech Calls Virtual 2026 AGM, Seeks Larger Supervisory Board to Back Oncology Push
8d ago
6K
BNTX
BioNTech price target lowered to $130 from $140 at H.C. Wainwright
PremiumThe Fly
BioNTech price target lowered to $130 from $140 at H.C. Wainwright
11d ago
BNTX
BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data
PremiumCompany Announcements
BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data
17d ago
6K
BNTX
District court rules federal limits to vaccines not based on science, NYT says
PremiumThe FlyDistrict court rules federal limits to vaccines not based on science, NYT says
25d ago
AZN
BMY
BioNTech price target lowered to $94 from $116 at TD Cowen
Premium
The Fly
BioNTech price target lowered to $94 from $116 at TD Cowen
1M ago
BNTX
BioNTech price target lowered to $125 from $134 at Morgan Stanley
Premium
The Fly
BioNTech price target lowered to $125 from $134 at Morgan Stanley
1M ago
BNTX
BioNTech price target lowered to $128 from $143 at BMO Capital
PremiumThe Fly
BioNTech price target lowered to $128 from $143 at BMO Capital
1M ago
BNTX
BioNTech price target lowered to $130 from $145 at Citi
PremiumThe Fly
BioNTech price target lowered to $130 from $145 at Citi
1M ago
BNTX
Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
PremiumRatings
Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
1M ago
BNTX
BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks
PremiumRatings
BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks
1M ago
BNTX
Jefferies cuts BioNTech price target, says stock is cheap
PremiumThe FlyJefferies cuts BioNTech price target, says stock is cheap
1M ago
BNTX
Clear Street lowers BioNTech price target, says buy on weakness
Premium
The Fly
Clear Street lowers BioNTech price target, says buy on weakness
1M ago
BNTX
BioNTech falls -19.9%
Premium
The Fly
BioNTech falls -19.9%
1M ago
BNTX
Midday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company
PremiumThe Fly
Midday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company
1M ago
ABM
CNC
BioNTech falls -20.3%
PremiumThe Fly
BioNTech falls -20.3%
1M ago
BNTX
Morning Movers: BioNTech sinks following departure of founders, Q4 results
PremiumThe Fly
Morning Movers: BioNTech sinks following departure of founders, Q4 results
1M ago
BG
HPE
BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline
PremiumCompany Announcements
BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline
1M ago
6K
BNTX
BioNTech Co-Founders to Launch Independent mRNA Venture as Company Refocuses on Late-Stage Pipeline
PremiumCompany AnnouncementsBioNTech Co-Founders to Launch Independent mRNA Venture as Company Refocuses on Late-Stage Pipeline
1M ago
6K
BNTX
BioNTech reports Q4 adjusted EPS EUR (0.33) vs. EUR 1.79 last year
Premium
The Fly
BioNTech reports Q4 adjusted EPS EUR (0.33) vs. EUR 1.79 last year
1M ago
BNTX
BioNTech sees FY26 revenue EUR 2B-EUR 2.3B
Premium
The Fly
BioNTech sees FY26 revenue EUR 2B-EUR 2.3B
1M ago
PFE
BNTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >